Friday 6 November 2026 Export IONS’s income statement to Excel — free account

Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $943.7 million, up 33.8% from fiscal 2024.

Revenue: −40.7%
EPS: −188.5%
Free cash flow: +299.3%
Total debt: +116.0%

Quarter to June 2026, against a year earlier

Insider buying

39.48 0.68 +1.75%

Follow IONS

Alert me

Market cap: $6.5B
P/E: 0.0×
Fwd P/E: −12.2×
Dividend yield: —
F-score: 4/9
Altman Z: 2.12
Beneish M: −3.13
Dividend safety: n/a

Overview Business Profile Segments Valuation Filings

Ionis Pharmaceuticals, Inc. 10-Q filed Jul 29, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed Jul 29, 2026 · accepted 5:05 PM ET · Document on sec.gov · Filing index

Red flags

Receivables outpacing revenue Jul 29, 2026
Receivables grew 11.9% while revenue grew -40.7% year over year

10-Q filed Jul 29, 2026 · The filing · sec.gov

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Jul 30, 2025: 14 added · 14 removed · 19 modified; 10 with only figures updated

Ionis Pharmaceuticals, Inc. 10-Q filed Jul 29, 2026

Red flags

What changed

Stockrow Weekly